Anixa Biosciences (ANIX) 10-Q 11 Mar 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jan. 31, 2021	Mar. 11, 2021
Cover [Abstract]
Entity Registrant Name	Anixa Biosciences Inc
Entity Central Index Key	0000715446
Document Type	10-Q
Document Period End Date	Jan. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,705,514
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Current assets:
Cash and cash equivalents	$ 11,982,870	$ 6,417,061
Short-term investments in certificates of deposit	2,000,000	2,640,000
Prepaid expenses and other current assets	581,320	311,563
Total current assets	14,564,190	9,368,624
Operating lease right-of-use asset	40,212	54,340
Other assets		30,000
Total assets	14,604,402	9,452,964
Current liabilities:
Accounts payable	511,816	232,368
Accrued expenses	972,835	901,025
Operating lease liability	40,836	55,198
Total current liabilities	1,525,487	1,188,591
Commitments and contingencies (Note 9)
Shareholders' equity:
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 26,179,122 and 24,248,695 shares issued and outstanding, respectively	261,791	242,486
Additional paid-in capital	207,382,102	200,354,488
Accumulated deficit	(194,043,909)	(191,835,618)
Total shareholders' equity	13,599,984	8,761,356
Noncontrolling interest (Note 1)	(521,069)	(496,983)
Total equity	13,078,915	8,264,373
Total liabilities and equity	14,604,402	9,452,964
Series A Convertible Preferred Stock [Member]
Shareholders' equity:
Preferred stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jan. 31, 2021	Oct. 31, 2020
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ .01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	26,179,122	24,248,695
Common stock, shares outstanding	26,179,122	24,248,695
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued
Preferred stock, shares outstanding

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Income Statement [Abstract]
Revenue	$ 512,500
Operating costs and expenses:
Inventor royalties, contingent legal fees, litigation and licensing expenses	385,002
Research and development expenses (including non-cash share-based compensation expenses of $290,207 and $397,523, respectively)	827,651	1,490,588
General and administrative expenses (including non-cash share-based compensation expenses of $695,892 and $623,811, respectively)	1,532,978	1,139,281
Total operating costs and expenses	2,745,631	2,629,869
Loss from operations	(2,233,131)	(2,629,869)
Interest income	754	13,294
Net loss	(2,232,377)	(2,616,575)
Less: Net loss attributable to noncontrolling interest	(24,086)	(24,032)
Net loss attributable to common shareholders	$ (2,208,291)	$ (2,592,543)
Net loss per common share attributable to common shareholders: Basic and diluted	$ (0.09)	$ (0.13)
Weighted average common shares outstanding: Basic and diluted	25,164,565	20,703,882

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Research and Development Expense [Member]
Non-cash share based compensation expenses	$ 290,207	$ 397,523
General and Administrative Expense [Member]
Non-cash share based compensation expenses	$ 695,892	$ 623,811

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total Shareholders' Equity [Member]	Non-controlling Interest [Member]	Total
Beginning balance at Oct. 31, 2019	$ 203,317	$ 186,849,299	$ (181,817,263)	$ 5,235,353	$ (422,975)	$ 4,812,378
Beginning balance, shares at Oct. 31, 2019	20,331,754
Stock option compensation to employees and directors		963,880		963,880		963,880
Stock options and warrants issued to consultants		57,454		57,454		57,454
Common stock issued upon exercise of stock options	$ 189	28,291		28,480		28,480
Common stock issued upon exercise of stock options, shares	18,900
Common stock issued in at-the-market offering	$ 4,907	1,747,076		1,751,983		1,751,983
Common stock issued in at-the-market offering, shares	490,655
Net loss			(2,592,543)	(2,592,543)	(24,032)	(2,616,575)
Ending balance at Jan. 31, 2020	$ 208,413	189,646,000	(184,409,806)	5,444,607	(447,007)	4,997,600
Ending balance, shares at Jan. 31, 2020	20,841,309
Beginning balance at Oct. 31, 2020	$ 242,486	200,354,488	(191,835,618)	8,761,356	(496,983)	8,264,373
Beginning balance, shares at Oct. 31, 2020	24,248,695
Stock option compensation to employees and directors		874,862		874,862		874,862
Stock options and warrants issued to consultants		111,237		111,237		111,237
Common stock issued upon exercise of stock options	$ 299	103,925		104,224		104,224
Common stock issued upon exercise of stock options, shares	29,880
Common stock issued in at-the-market offering	$ 19,006	5,937,590		5,956,596		5,956,596
Common stock issued in at-the-market offering, shares	1,900,547
Net loss			(2,208,291)	(2,208,291)	(24,086)	(2,232,377)
Ending balance at Jan. 31, 2021	$ 261,791	$ 207,382,102	$ (194,043,909)	$ 13,599,984	$ (521,069)	$ 13,078,915
Ending balance, shares at Jan. 31, 2021	26,179,122

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Statement of Stockholders' Equity [Abstract]
Stock issued, offering expenses	$ 184,510	$ 100,972

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (2,232,377)	$ (2,616,575)
Stock option compensation to employees and directors	874,862	963,880
Stock options and warrants issued to consultants	111,237	57,454
Depreciation of property and equipment		14,998
Gain on sale of equipment	(5,447)
Amortization of operating lease right-to-use asset	14,128	12,314
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(269,757)	74,698
Accounts payable	279,448	(218,719)
Accrued expenses	71,810	(190,464)
Operating lease liability	(14,362)	(12,002)
Net cash used in operating activities	(1,170,458)	(1,914,416)
Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit	(1,000,000)	(1,870,000)
Proceeds from maturities of short-term investments in certificates of deposit	1,640,000	1,350,000
Purchase of property and equipment		(15,790)
Proceeds from sale of equipment	35,447
Net cash provided by (used in) investing activities	675,447	(535,790)
Cash flows from financing activities:
Net proceeds from sale of common stock in at-the-market offering	5,956,596	1,751,983
Proceeds from exercise of stock options	104,224	28,480
Net cash provided by financing activities	6,060,820	1,780,463
Net increase (decrease) in cash and cash equivalents	5,565,809	(669,743)
Cash and cash equivalents at beginning of period	6,417,061	3,491,625
Cash and cash equivalents at end of period	11,982,870	2,821,882
Supplemental cash flow information:
Cash proceeds from interest income	$ 1,134	$ 14,468

Business and Funding

Business and Funding	3 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Business and Funding	1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, and discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include the development of a vaccine against breast cancer, specifically triple negative breast cancer (“TNBC”), the most lethal form of the disease, and a vaccine against ovarian cancer. Our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”) relating to Wistar’s CAR-T technology. We have initially focused on the development of a treatment for ovarian cancer, but we may also pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent (5%) of the common stock of Certainty. Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing its CAR-T technology for treating ovarian cancer. We are currently testing the clinical grade vector and preparing an Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”). We anticipate filing the IND in the first calendar quarter of 2021. Assuming the FDA approves our IND application, we anticipate beginning the human clinical trials during the second half of 2021. In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”), to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform in silico The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus. Several of these compounds were synthesized and tested in in vitro We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. We are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. A specific protein, alpha-lactalbumin, has been identified that is only present during lactation in healthy women, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In December 2020, we received authorization from the FDA to commence enrollment and treatment of patients in a Phase 1a clinical trial. We are performing the activities necessary to prepare for treatment of patients in the Phase 1a clinical trial, and we anticipate being prepared to treat the first enrolled patient by mid-year 2021. In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor II protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic, to advance this vaccine technology toward human clinical testing. Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding the Cchek™ liquid biopsy platform (operations for which were suspended in July 2020), as well as in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials. Funding and Management’s Plans Based on currently available information as of March 11, 2021, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the three months ended January 31, 2021, we raised approximately $5,957,000, net of expenses, through an at-the-market equity offering of 1,900,547 shares of common stock, under which offering we may issue up to $50 million of common stock. Under our at-the-market equity program which is currently effective and may remain available for us to use in the future, as of January 31, 2021, we may sell an additional approximately $34,670,000 of common stock. We may seek to obtain working capital during our fiscal year 2021 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt could result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2020. The accompanying October 31, 2020 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2021, and results of operations and cash flows for the interim periods represented. The results of operations for the three months ended January 31, 2021 are not necessarily indicative of the results to be expected for the entire year. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2021: Balance, October 31, 2020 $ (496,983 ) Net loss attributable to noncontrolling interest (24,086 ) Balance, January 31, 2021 $ (521,069 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. We follow the accounting guidance of Accounting Standards Codification 606 (“ASC 606”), Revenue from Contracts with Customers. In accordance with ASC 606 we are required to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements. Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, preventative cancer vaccines and anti-viral drug candidates for COVID-19, are expensed in the accompanying condensed consolidated financial statements in the period incurred.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Jan. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	2. STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to four years. We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately $875,000 and $964,000 during the three months ended January 31, 2021 and 2020. For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On May 8, 2018, we issued market condition options to purchase 1,500,000 shares of common stock, to our Chairman, President and Chief Executive Officer, vesting at target trading prices of $5.00 to $8.00 per share before May 31, 2021, with implied service periods of three to seven months. In October 2018, the first tranche of 500,000 shares of market condition options became exercisable upon achieving an average closing price above $5.00 per share for twenty consecutive trading days. We did not record any market condition stock-based compensation expense during the three months ended January 31, 2021 and 2020. The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $54,000 and $57,000 during the three months ended January 31, 2021 and 2020, respectively. Stock Option Plans During the three months ended January 31, 2021, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. During the three months ended January 31, 2020, the remaining outstanding options under the Anixa Biosciences, Inc. 2003 Share Incentive Plan (the “2003 Plan”) expired. Stock Option Activity During the three months ended January 31, 2021 and 2020, we granted options to purchase 1,130,000 shares and 800,000 shares of common stock, respectively, to employees and consultants, with exercise prices ranging from $2.83 to $4.04 per share, pursuant to the 2018 Share Plan. During the three months ended January 31, 2021 and 2020, stock options to purchase 29,880 and 18,900 shares of common stock, respectively, were exercised with aggregate proceeds of approximately $104,000 and $28,000, respectively. 2003 Plan The 2003 Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2003 Plan, the plan terminated with respect to the ability to grant future awards on April 21, 2013. Information regarding the 2003 Plan for the three months ended January 31, 2020 is as follows: Shares Weighted Aggregate Intrinsic Options outstanding at October 31, 2019 400 $ 17.00 Forfeited/Expired (400 ) $ 17.00 Options outstanding and exercisable at January 31, 2020 - $ -0- $ -0- 2010 Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the three months ended January 31, 2021 is as follows: Shares Weighted Aggregate Options outstanding at October 31, 2020 1, 1,907,534 $ 2.82 Exercised (6,000 ) $ 2.32 Forfeited/Expired (400 ) $ 5.75 Options outstanding at January 31, 2021 1 1,901,134 $ 2.82 $ 1,906,253 Options exercisable at January 31, 2021 1, 1,823,634 $ 2.83 $ 1,822,053 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2021: Options Outstanding Options Exercisable Range of Number Weighted Weighted Number Weighted Weighted $ 0.67 - $ 2.30 544,000 5.22 $ 1.56 516,500 5.15 $ 1.60 $ 2.58 - $ 3.13 833,000 3.11 $ 2.79 833,000 3.54 $ 2.79 $ 3.46 - $ 5.30 524,134 7.11 $ 4.17 474,134 7.07 $ 4.25 Information regarding the 2010 Share Plan for the three months ended January 31, 2020 is as follows: Shares Weighted Aggregate Options Outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised (18,900 ) $ 1.51 Forfeited/Expired (5,534 ) $ 2.58 Options Outstanding at January 31, 2020 1,974,234 $ 2.81 $ 1,810,395 Options Exercisable at January 31, 2020 1,721,734 $ 2.86 $ 1,542,195 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2020: Options Outstanding Options Exercisable Range of Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.67 - $2.30 561,500 6.28 $ 1.56 464,000 6.03 $ 1.69 $ 2.58 - $ 3.13 878,200 3.43 $ 2.79 878,200 3.97 $ 2.79 $ 3.46 - $ 5.75 534,534 7.94 $ 4.16 379,534 7.76 $ 4.45 2018 Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of January 31, 2021, the 2018 Share Plan had 2,000,000 shares available for future grants. Information regarding the 2018 Share Plan for the three months ended January 31, 2021 is as follows: Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2020 4,346,661 $ 3.69 Granted 1,130,000 $ 2.83 Exercised (23,880 ) $ 3.78 Forfeited/Expired (392,781 ) $ 3.70 Options outstanding at January 31, 2021 5,060,000 $ 3.49 $ 1,184,900 Options exercisable at January 31, 2021 2,312,640 $ 3.69 $ 147,579 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2021: Options Outstanding Options Exercisable Range of Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.09 - $3.70 3,975,000 8.12 $ 3.38 1,664,862 7.47 $ 3.61 $ 3.84 - $4.61 1,085,000 7.95 $ 3.90 647,778 7.66 $ 3.92 Information regarding the 2018 Share Plan for the three months ended January 31, 2020 is as follows: Shares Weighted Aggregate Intrinsic Value Options Outstanding at October 31, 2019 3,935,500 $ 3.74 Granted 800,000 $ 3.85 Options Outstanding at January 31, 2020 4,735,000 $ 3.76 $ -0- Options Exercisable at January 31, 2020 1,798,616 $ 3.74 $ -0- The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 3.70 3,100,000 8.27 $ 3.70 1,433,334 8.27 $ 3.70 $ 3.84 - $4.61 1,635,000 9.17 $ 3.88 365,282 8.32 $ 3.92 Outside of Share Plans In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors. Information regarding stock options that were granted outside of share plans for the three months ended January 31, 2021 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2020 1,698,000 $ 2.58 Options outstanding and exercisable at January 31, 2021 1,698,000 $ 2.58 $ 1,825,350 The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2021: Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.58 1,698,000 1.56 $ 2.58 Information regarding stock options that were granted outside of Share Plans for the three months ended January 31, 2020 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2019 1,698,000 $ 2.58 Options outstanding and exercisable at January 31, 2020 1,698,000 $ 2.58 $ 1,655,550 The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2020: Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.58 1,698,000 2.50 $ 2.58 Stock Awards For stock awards granted to employees, directors and consultants that vest upon grant we recognize expense at the date of grant based on the grant date market price of the underlying common stock. We did not grant any stock awards that vested upon grant during the three months ended January 31, 2021 or 2020. On May 8, 2018, a restricted stock award of 1,500,000 shares of common stock was granted under the 2018 Share Plan to our Chairman, President and Chief Executive Officer. The restricted stock award vests in its entirety upon achievement of a target trading price of $11.00 per share of the Company’s common stock before May 31, 2021. For restricted stock awards vesting upon achievement of a price target of our common stock we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). We did not record any compensation expense related to the restricted stock award during the three months ended January 31, 2021 and 2020. Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (“ESPP”) which permits eligible employees to purchase shares at not less than 85% of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the three months ended January 31, 2021 and 2020, no shares were purchased under the ESPP. Warrants On October 30, 2020 we issued a warrant, expiring on October 30, 2025, to purchase 60,000 shares of common stock at $2.06 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately $57,000 during the three months ended January 31, 2021, based on the fair value of the warrant on the date of grant recognized on a straight-line basis over the vesting period. We did not record any consulting expense related to warrants during the three months ended January 31, 2020. No warrants were issued during the three-month periods ended January 31, 2021 and 2020. As of January 31, 2021, we also had warrants outstanding to purchase 500,000 shares of common stock at $5.03 per share, issued during fiscal year 2017 and expiring on November 30, 2021.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jan. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 - Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 - Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2021: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 11,568,608 $ - $ - $ 11,568,608 Certificates of deposit: Cash and cash equivalents 250,000 - - 250,000 Short-term investments - 2,000,000 - 2,000,000 Total financial assets $ 11,818,608 $ 2,000,000 $ - $ 13,818,608 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 3,902,292 $ - $ - $ 3,902,292 Certificates of deposit: Cash and cash equivalents 2,250,000 - - 2,250,000 Short-term investments - 2,640,000 - 2,640,000 Total financial assets $ 6,152,292 $ 2,640,000 $ - $ 8,792,292 Our non-financial assets that are measured on a non-recurring basis include our other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash and cash equivalents are stated at carrying value which approximates fair value.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Jan. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	4. ACCRUED EXPENSES Accrued expenses consist of the following as of: January 31, October 31, 2021 2020 Payroll and related expenses $ 228,163 $ 415,331 Accrued royalty and contingent legal fees 577,190 449,691 Accrued collaborative research and license expense 147,410 30,000 Accrued other 20,072 6,003 $ 972,835 $ 901,025

Net Loss Per Share of Common St

Net Loss Per Share of Common Stock	3 Months Ended
	Jan. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share of Common Stock	5. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the three months ended January 31, 2021 and 2020, were stock options to purchase 8,659,134 and 8,407,234 shares, respectively, and warrants to purchase 560,000 and 500,000 shares, respectively.

Effect of Recently Adopted and

Effect of Recently Adopted and Issued Pronouncements	3 Months Ended
	Jan. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Effect of Recently Adopted and Issued Pronouncements	6. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2016-02 (“ASU 2016-02”) Accounting Standards Codification Topic 842, Leases (ASC 842), which supersedes Topic 840, Leases, and which requires lessees to recognize most leases on the balance sheet. The new lease standard does not substantially change lessor accounting. For public companies, the standard was effective for the first interim reporting period within annual periods beginning after December 15, 2018, although early adoption was permitted. Lessees and lessors were required to apply the new standard at the beginning of the earliest period presented in the financial statements in which they first apply the new guidance. In July 2018, FASB issued ASU 2018-11, Leases, which provides an additional transition option for an entity to apply the provisions of ASC 842 by recognizing a cumulative effect adjustment at the effective date of adoption without adjusting the prior comparative periods presented. The requirements of this standard include a significant increase in required disclosures. The Company adopted ASU 2016-02 on November 1, 2019. The adoption of this standard did not have a material impact on our condensed consolidated financial statements. See Note 8 regarding the accounting and disclosures related to our office lease.

Income Taxes

Income Taxes	3 Months Ended
	Jan. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	7. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no unrecognized income tax benefits as of January 31, 2021 and October 31, 2020 and we account for interest and penalties related to income tax matters, if any, in general and administrative expenses.

Leases

Leases	3 Months Ended
	Jan. 31, 2021
Leases [Abstract]
Leases	8. LEASES We lease approximately 2,000 square feet of office space at 3150 Almaden Expressway, San Jose, California (our principal executive offices) from an unrelated party pursuant to an operating lease that expires September 30, 2021. Our base rent is approximately $5,000 per month and the lease provides for annual increases of approximately 3% and an escalation clause for increases in certain operating costs. Rent expense was approximately $16,000 and $16,000, respectively, for the three months ended January 31, 2021 and 2020. On November 1, 2019, the Company adopted ASC 842, which increases transparency and comparability by recognizing a lessee’s rights and obligations resulting from leases by recording them on the balance sheet as lease assets and lease liabilities. The new guidance requires the recognition of the right-of-use (“ROU”) assets and related operating lease liabilities on the balance sheet. The Company adopted the new guidance using the modified retrospective approach on November 1, 2019. The Company elected the package of practical expedients permitted within the standard, which allow an entity to forgo reassessing (i) whether a contract contains a lease, (ii) classification of leases, and (iii) whether capitalized costs associated with a lease meet the definition of initial direct costs. Also, the Company elected the expedient allowing an entity to use hindsight to determine the lease term and impairment of ROU assets and the expedient to allow the Company to not have to separate lease and non-lease components. The Company has also elected the short-term lease accounting policy under which Anixa would not recognize a lease liability or ROU asset for any lease that at the commencement date has a lease term of twelve months or less and does not include a purchase option that Anixa is more than reasonably certain to exercise. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 8-month lease term as of January 31, 2021 for the Company’s lease includes the noncancelable period of the lease. The lease does not contain a Company option to extend the lease or an option to extend the lease controlled by the lessor. All ROU assets are reviewed for impairment. Balance sheet information related to the Company’s lease is presented below: Balance Sheet January 31, October 31, Operating Lease: Right-of-use asset Operating lease right-of-use asset $ 40,212 $ 54,340 Right-of-use liability, current Operating lease liability 40,836 55,198 As of January 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows: Operating Leases 2021 future minimum payments, undiscounted $ 43,008 Less: Imputed interest (2,172 ) Present value of future minimum lease payments $ 40,836

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. COMMITMENTS AND CONTINGENCES Litigation Matters We are not involved in any litigation or other legal proceedings and management is not aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition. Impact of Coronavirus Pandemic On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had and are expected to continue to have a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company’s partners operate and conduct their business. We are currently following the recommendations of local health authorities to minimize exposure risk for our team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that our continuity plans will be successful. We have already experienced certain disruptions to our business such as temporary closure of our offices and similar disruptions have occurred for our partners. Specifically, the outbreak has caused temporary shutdowns of the laboratories and other service providers that we rely on to develop our programs, and those laboratories and service providers that have been operating or that have begun operating recently have been doing so with more limited capacity due to social distancing requirements. As a result, our progress has been slowed and there is no assurance that we will be able to meet our previously announced timelines regarding the advancement of our programs. The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition and prospects.

Segment Information

Segment Information	3 Months Ended
	Jan. 31, 2021
Segment Reporting [Abstract]
Segment Information	10. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021 and October 31, 2020: For the Three Months Ended 2021 2020 Net loss: CAR-T Therapeutics $ (960,736 ) $ (630,333 ) Cancer Vaccines (906,336 ) (195,596 ) Anti-Viral Therapeutics (480,806 ) - Cancer Diagnostics (8,962 ) (1,790,646 ) Patent Licensing 124,463 - Total $ (2,232,377 ) $ (2,616,575 ) Total operating costs and expenses $ 2,745,631 $ 2,629,869 Less non-cash share-based compensation (986,099 ) (1,021,334 ) Operating costs and expenses excluding non-cash share-based compensation $ 1,759,532 $ 1,608,535 Operating costs and expenses excluding non-cash share based compensation expense: CAR-T Therapeutics $ 557,680 $ 346,341 Cancer Vaccines 537,988 98,270 Anti-Viral Therapeutics 270,256 - Cancer Diagnostics 6,432 1,163,924 Patent Licensing 387,176 - Total $ 1,759,532 $ 1,608,535 January 31, October 31, Total assets: CAR-T Therapeutics $ 5,849,920 $ 2,988,124 Cancer Vaccines 5,822,106 946,923 Anti-Viral Therapeutics 2,775,760 2,464,361 Cancer Diagnostics 85,463 2,869,529 Patent Licensing 71,153 184,027 Total $ 14,604,402 $ 9,452,964 Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise. The Company’s consolidated revenue of $512,500 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,002 for the three months ended January 31, 2021 were solely related to our patent licensing segment which consists of our encrypted audio/video conference calling technology. All our revenue is generated domestically (United States) based on the country in which the licensee is located.

Business and Funding (Tables)

Business and Funding (Tables)	3 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Schedule of Changes in Noncontrolling Interest	Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2021: Balance, October 31, 2020 $ (496,983 ) Net loss attributable to noncontrolling interest (24,086 ) Balance, January 31, 2021 $ (521,069 )

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Jan. 31, 2021
Schedule of Option Activity	Information regarding stock options that were granted outside of share plans for the three months ended January 31, 2021 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2020 1,698,000 $ 2.58 Options outstanding and exercisable at January 31, 2021 1,698,000 $ 2.58 $ 1,825,350 Information regarding stock options that were granted outside of Share Plans for the three months ended January 31, 2020 is as follows: Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Options outstanding at October 31, 2019 1,698,000 $ 2.58 Options outstanding and exercisable at January 31, 2020 1,698,000 $ 2.58 $ 1,655,550
Schedule of Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2021: Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.58 1,698,000 1.56 $ 2.58 The following table summarizes information about stock options outstanding and exercisable that were granted outside of Share Plans as of January 31, 2020: Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.58 1,698,000 2.50 $ 2.58
2003 Plan [Member]
Schedule of Option Activity	Information regarding the 2003 Plan for the three months ended January 31, 2020 is as follows: Shares Weighted Aggregate Intrinsic Options outstanding at October 31, 2019 400 $ 17.00 Forfeited/Expired (400 ) $ 17.00 Options outstanding and exercisable at January 31, 2020 - $ -0- $ -0-
2010 Plan [Member]
Schedule of Option Activity	Information regarding the 2010 Share Plan for the three months ended January 31, 2021 is as follows: Shares Weighted Aggregate Options outstanding at October 31, 2020 1, 1,907,534 $ 2.82 Exercised (6,000 ) $ 2.32 Forfeited/Expired (400 ) $ 5.75 Options outstanding at January 31, 2021 1 1,901,134 $ 2.82 $ 1,906,253 Options exercisable at January 31, 2021 1, 1,823,634 $ 2.83 $ 1,822,053 Information regarding the 2010 Share Plan for the three months ended January 31, 2020 is as follows: Shares Weighted Aggregate Options Outstanding at October 31, 2019 1,998,668 $ 2.80 Exercised (18,900 ) $ 1.51 Forfeited/Expired (5,534 ) $ 2.58 Options Outstanding at January 31, 2020 1,974,234 $ 2.81 $ 1,810,395 Options Exercisable at January 31, 2020 1,721,734 $ 2.86 $ 1,542,195
Schedule of Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2021: Options Outstanding Options Exercisable Range of Number Weighted Weighted Number Weighted Weighted $ 0.67 - $ 2.30 544,000 5.22 $ 1.56 516,500 5.15 $ 1.60 $ 2.58 - $ 3.13 833,000 3.11 $ 2.79 833,000 3.54 $ 2.79 $ 3.46 - $ 5.30 524,134 7.11 $ 4.17 474,134 7.07 $ 4.25 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2020: Options Outstanding Options Exercisable Range of Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.67 - $2.30 561,500 6.28 $ 1.56 464,000 6.03 $ 1.69 $ 2.58 - $ 3.13 878,200 3.43 $ 2.79 878,200 3.97 $ 2.79 $ 3.46 - $ 5.75 534,534 7.94 $ 4.16 379,534 7.76 $ 4.45
2018 Plan [Member]
Schedule of Option Activity	Information regarding the 2018 Share Plan for the three months ended January 31, 2021 is as follows: Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2020 4,346,661 $ 3.69 Granted 1,130,000 $ 2.83 Exercised (23,880 ) $ 3.78 Forfeited/Expired (392,781 ) $ 3.70 Options outstanding at January 31, 2021 5,060,000 $ 3.49 $ 1,184,900 Options exercisable at January 31, 2021 2,312,640 $ 3.69 $ 147,579 Information regarding the 2018 Share Plan for the three months ended January 31, 2020 is as follows: Shares Weighted Aggregate Intrinsic Value Options Outstanding at October 31, 2019 3,935,500 $ 3.74 Granted 800,000 $ 3.85 Options Outstanding at January 31, 2020 4,735,000 $ 3.76 $ -0- Options Exercisable at January 31, 2020 1,798,616 $ 3.74 $ -0-
Schedule of Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2021: Options Outstanding Options Exercisable Range of Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 2.09 - $3.70 3,975,000 8.12 $ 3.38 1,664,862 7.47 $ 3.61 $ 3.84 - $4.61 1,085,000 7.95 $ 3.90 647,778 7.66 $ 3.92 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 3.70 3,100,000 8.27 $ 3.70 1,433,334 8.27 $ 3.70 $ 3.84 - $4.61 1,635,000 9.17 $ 3.88 365,282 8.32 $ 3.92

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jan. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurements	The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2021: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 11,568,608 $ - $ - $ 11,568,608 Certificates of deposit: Cash and cash equivalents 250,000 - - 250,000 Short-term investments - 2,000,000 - 2,000,000 Total financial assets $ 11,818,608 $ 2,000,000 $ - $ 13,818,608 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2020: Level 1 Level 2 Level 3 Total Money market funds: Cash and cash equivalents $ 3,902,292 $ - $ - $ 3,902,292 Certificates of deposit: Cash and cash equivalents 2,250,000 - - 2,250,000 Short-term investments - 2,640,000 - 2,640,000 Total financial assets $ 6,152,292 $ 2,640,000 $ - $ 8,792,292

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Jan. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following as of: January 31, October 31, 2021 2020 Payroll and related expenses $ 228,163 $ 415,331 Accrued royalty and contingent legal fees 577,190 449,691 Accrued collaborative research and license expense 147,410 30,000 Accrued other 20,072 6,003 $ 972,835 $ 901,025

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jan. 31, 2021
Leases [Abstract]
Schedule of Operating Lease	Balance sheet information related to the Company’s lease is presented below: Balance Sheet January 31, October 31, Operating Lease: Right-of-use asset Operating lease right-of-use asset $ 40,212 $ 54,340 Right-of-use liability, current Operating lease liability 40,836 55,198
Schedule of Minimum Lease Payments	As of January 31, 2021, the annual minimum lease payments of our operating lease liabilities were as follows: Operating Leases 2021 future minimum payments, undiscounted $ 43,008 Less: Imputed interest (2,172 ) Present value of future minimum lease payments $ 40,836

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Jan. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Information	The following represents selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021 and October 31, 2020: For the Three Months Ended 2021 2020 Net loss: CAR-T Therapeutics $ (960,736 ) $ (630,333 ) Cancer Vaccines (906,336 ) (195,596 ) Anti-Viral Therapeutics (480,806 ) - Cancer Diagnostics (8,962 ) (1,790,646 ) Patent Licensing 124,463 - Total $ (2,232,377 ) $ (2,616,575 ) Total operating costs and expenses $ 2,745,631 $ 2,629,869 Less non-cash share-based compensation (986,099 ) (1,021,334 ) Operating costs and expenses excluding non-cash share-based compensation $ 1,759,532 $ 1,608,535 Operating costs and expenses excluding non-cash share based compensation expense: CAR-T Therapeutics $ 557,680 $ 346,341 Cancer Vaccines 537,988 98,270 Anti-Viral Therapeutics 270,256 - Cancer Diagnostics 6,432 1,163,924 Patent Licensing 387,176 - Total $ 1,759,532 $ 1,608,535 January 31, October 31, Total assets: CAR-T Therapeutics $ 5,849,920 $ 2,988,124 Cancer Vaccines 5,822,106 946,923 Anti-Viral Therapeutics 2,775,760 2,464,361 Cancer Diagnostics 85,463 2,869,529 Patent Licensing 71,153 184,027 Total $ 14,604,402 $ 9,452,964

Business and Funding (Details N

Business and Funding (Details Narrative) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Shares of common stock, value	$ 5,956,596	$ 1,751,983
Our at-the-Market Equity Offerings [Member]
Net of expenses	$ 5,957,000
Sale of shares of common stock	1,900,547
An at-the-Market Equity Offerings [Member]
Shares of common stock, value	$ 50,000,000
Sale of shares of common stock, value	$ 34,670,000
Wistar Institute [Member]
Ownership Percentage	5.00%

Business and Funding - Schedule

Business and Funding - Schedule of Changes in Noncontrolling Interest (Details) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Accounting Policies [Abstract]
Balance	$ (496,983)
Net loss attributable to noncontrolling interest	(24,086)	$ (24,032)
Balance	$ (521,069)

Stock Based Compensation (Detai

Stock Based Compensation (Details Narrative)	Oct. 30, 2020$ / sharesshares	May 08, 2018$ / sharesshares	Oct. 31, 2018Days$ / sharesshares	Jan. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2020USD ($)$ / sharesshares
Stock option compensation to employees and directors | $				$ 874,862	$ 963,880
Weighted average exercise per share | $ / shares
Shares options, granted
Stock options exercised | $				$ 104,224	$ 28,480
Warrants [Member]
Vesting period	5 months
Warrant expiration date	Oct. 30, 2025			Nov. 30, 2021
Warrants purchase of common stock shares	60,000
Warrant exercise price | $ / shares	$ 2.06			$ 5.03
Consulting expense | $				$ 57,000
Warrants issued
Warrants outstanding				500,000
Stock Option [Member]
Stock options exercised, shares				29,880	18,900
Stock options exercised | $				$ 104,000	$ 28,000
2018 Plan [Member]
Weighted average exercise per share | $ / shares				$ 3.78
Shares options, granted				1,130,000	800,000
Stock options exercised, shares				23,880
Shares available for future grants				2,000,000
First Tranche [Member]
Option to purchase common stock			500,000
Weighted average exercise per share | $ / shares			$ 5
Consecutive trading days | Days			20
Employees and Directors [Member] | Minimum [Member]
Vesting period				1 year
Employees and Directors [Member] | Maximum [Member]
Vesting period				4 years
Chairman, President and Chief Executive Officer [Member]
Option to purchase common stock		1,500,000
Expiration date		May 31, 2021
Chairman, President and Chief Executive Officer [Member] | 2018 Plan [Member] | Restricted Stock [Member]
Option to purchase common stock		1,500,000
Weighted average exercise per share | $ / shares		$ 11
Expiration date		May 31, 2021
Chairman, President and Chief Executive Officer [Member] | Minimum [Member]
Weighted average exercise per share | $ / shares		$ 5
Service period		3 months
Chairman, President and Chief Executive Officer [Member] | Maximum [Member]
Weighted average exercise per share | $ / shares		$ 8
Service period		7 months
Consultants [Member]
Stock option compensation to employees and directors | $				$ 57,000	$ 54,000
Employees and Consultants [Member] | 2018 Plan [Member]
Shares options, granted				1,130,000	800,000
Employees and Consultants [Member] | Minimum [Member] | 2018 Plan [Member]
Exercise price | $ / shares				$ 2.83
Employees and Consultants [Member] | Maximum [Member] | 2018 Plan [Member]
Exercise price | $ / shares				$ 4.04

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Option Activity (Details) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Shares, Options outstanding, Beginning balance	1,698,000	1,698,000
Shares, Options, Granted
Shares, Options, Forfeited/Expired
Shares, Options outstanding and Exercisable	1,698,000	1,698,000
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 2.58	$ 2.58
Weighted Average Exercise Price Per Share, Exercised
Weighted Average Exercise Price Per Share, Outstanding and Exercisable	$ 2.58	$ 2.58
Aggregate Intrinsic Value, Outstanding and Exercisable	$ 1,825,350	$ 1,655,550
2003 Plan [Member]
Shares, Options outstanding, Beginning balance	400
Shares, Options, Forfeited/Expired	(400)
Shares, Options outstanding, Ending balance
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 17
Weighted Average Exercise Price Per Share, Forfeited/Expired	17
Weighted Average Exercise Price Per Share, Outstanding Ending balance	$ 0
Aggregate Intrinsic Value, Outstanding and Exercisable	$ 0
2010 Plan [Member]
Shares, Options outstanding, Beginning balance	11,907,534	1,998,668
Shares, Options, Exercised	(6,000)	(18,900)
Shares, Options, Forfeited/Expired	(400)	(5,534)
Shares, Options outstanding, Ending balance	11,901,134	1,974,234
Shares, Options outstanding, Exercisable	11,823,634	1,721,734
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 2.82	$ 2.80
Weighted Average Exercise Price Per Share, Exercised	2.32	1.51
Weighted Average Exercise Price Per Share, Forfeited/Expired	5.75	2.58
Weighted Average Exercise Price Per Share, Outstanding Ending balance	2.82	2.81
Weighted Average Exercise Price Per Share, Exercisable	$ 2.83	$ 2.86
Aggregate Intrinsic Value, Outstanding Ending balance	$ 1,906,253	$ 1,810,395
Aggregate Intrinsic Value, Exercisable	$ 1,822,053	$ 1,542,195
2018 Plan [Member]
Shares, Options outstanding, Beginning balance	4,346,661	3,935,500
Shares, Options, Granted	1,130,000	800,000
Shares, Options, Exercised	(23,880)
Shares, Options, Forfeited/Expired	(392,781)
Shares, Options outstanding, Ending balance	5,060,000	4,735,000
Shares, Options outstanding, Exercisable	2,312,640	1,798,616
Weighted Average Exercise Price Per Share, Outstanding Beginning balance	$ 3.69	$ 3.74
Weighted Average Exercise Price Per Share, Granted	2.83	3.85
Weighted Average Exercise Price Per Share, Exercised	3.78
Weighted Average Exercise Price Per Share, Forfeited/Expired	3.70
Weighted Average Exercise Price Per Share, Outstanding Ending balance	3.49	3.76
Weighted Average Exercise Price Per Share, Exercisable	$ 3.69	$ 3.74
Aggregate Intrinsic Value, Outstanding Ending balance	$ 1,184,900	$ 0
Aggregate Intrinsic Value, Exercisable	$ 147,579	$ 0

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Outstanding and Exercisable (Details) - $ / shares	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020	Oct. 31, 2019
Number of Outstanding			1,698,000	1,698,000
Weighted Average Exercise Price			$ 2.58	$ 2.58
2010 Plan [Member]
Number of Outstanding	11,901,134	1,974,234	11,907,534	1,998,668
Weighted Average Exercise Price	$ 2.82	$ 2.81	$ 2.82	$ 2.80
Number Exercisable, Options Exercisable	11,823,634	1,721,734
Weighted Average Exercise Price, Options Exercisable	$ 2.83	$ 2.86
2010 Plan [Member] | Range 1 [Member]
Range of Exercise Prices, Lower limit	0.67	0.67
Range of Exercise Prices, Upper limit	$ 2.30	$ 2.30
Number of Outstanding	544,000	561,500
Weighted Average Remaining Contractual Life (in years)	5 years 2 months 19 days	6 years 3 months 11 days
Weighted Average Exercise Price	$ 1.56	$ 1.56
Number Exercisable, Options Exercisable	516,500	464,000
Weighted Average Remaining Contractual Life (in years), Options Exercisable	5 years 1 month 24 days	6 years 11 days
Weighted Average Exercise Price, Options Exercisable	$ 1.60	$ 1.69
2010 Plan [Member] | Range 2 [Member]
Range of Exercise Prices, Lower limit	2.58	2.58
Range of Exercise Prices, Upper limit	$ 3.13	$ 3.13
Number of Outstanding	833,000	878,200
Weighted Average Remaining Contractual Life (in years)	3 years 1 month 9 days	3 years 5 months 5 days
Weighted Average Exercise Price	$ 2.79	$ 2.79
Number Exercisable, Options Exercisable	833,000	878,200
Weighted Average Remaining Contractual Life (in years), Options Exercisable	3 years 6 months 14 days	3 years 11 months 19 days
Weighted Average Exercise Price, Options Exercisable	$ 2.79	$ 2.79
2010 Plan [Member] | Range 3 [Member]
Range of Exercise Prices, Lower limit	3.46	3.46
Range of Exercise Prices, Upper limit	$ 5.30	$ 5.75
Number of Outstanding	524,134	534,534
Weighted Average Remaining Contractual Life (in years)	7 years 1 month 9 days	7 years 11 months 8 days
Weighted Average Exercise Price	$ 4.17	$ 4.16
Number Exercisable, Options Exercisable	474,134	379,534
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 26 days	7 years 9 months 3 days
Weighted Average Exercise Price, Options Exercisable	$ 4.25	$ 4.45
2018 Plan [Member]
Number of Outstanding	5,060,000	4,735,000	4,346,661	3,935,500
Weighted Average Exercise Price	$ 3.49	$ 3.76	$ 3.69	$ 3.74
Number Exercisable, Options Exercisable	2,312,640	1,798,616
Weighted Average Exercise Price, Options Exercisable	$ 3.69	$ 3.74
2018 Plan [Member] | Range 1 [Member]
Range of Exercise Prices, Lower limit	2.09
Range of Exercise Prices, Upper limit	$ 3.70
Exercise Prices		3.70
Number of Outstanding	3,975,000	3,100,000
Weighted Average Remaining Contractual Life (in years)	8 years 1 month 13 days	8 years 3 months 8 days
Weighted Average Exercise Price	$ 3.38	$ 3.70
Number Exercisable, Options Exercisable	1,664,862	1,433,334
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 11 months 12 days	8 years 3 months 8 days
Weighted Average Exercise Price, Options Exercisable	$ 3.61	$ 3.70
2018 Plan [Member] | Range 2 [Member]
Range of Exercise Prices, Lower limit	3.84	3.84
Range of Exercise Prices, Upper limit	$ 4.61	$ 4.61
Number of Outstanding	1,085,000	1,635,000
Weighted Average Remaining Contractual Life (in years)	7 years 11 months 12 days	9 years 2 months 1 day
Weighted Average Exercise Price	$ 3.90	$ 3.88
Number Exercisable, Options Exercisable	647,778	365,282
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 7 months 28 days	8 years 3 months 26 days
Weighted Average Exercise Price, Options Exercisable	$ 3.92	$ 3.92
Outside of Share Plans [Member] | Range 1 [Member]
Range of Exercise Prices, Lower limit	$ 2.58	$ 2.58
Options Outstanding and Exercisable	1,698,000	1,698,000
Weighted Average Remaining Contractual Life (in years)	1 year 6 months 21 days	2 years 6 months
Weighted Average Exercise Price	$ 2.58	$ 2.58

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value Measurements (Details) - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Money market funds: Cash and cash equivalents	$ 11,568,608	$ 3,902,292
Certificates of deposit: Cash and cash equivalents	250,000	2,250,000
Short-term investments	2,000,000	2,640,000
Total financial assets	13,818,608	8,792,292
Level 1 [Member]
Money market funds: Cash and cash equivalents	11,568,608	3,902,292
Certificates of deposit: Cash and cash equivalents	250,000	2,250,000
Short-term investments
Total financial assets	11,818,608	6,152,292
Level 2 [Member]
Money market funds: Cash and cash equivalents
Certificates of deposit: Cash and cash equivalents
Short-term investments	2,000,000	2,640,000
Total financial assets	2,000,000	2,640,000
Level 3 [Member]
Money market funds: Cash and cash equivalents
Certificates of deposit: Cash and cash equivalents
Short-term investments
Total financial assets

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Payables and Accruals [Abstract]
Payroll and related expenses	$ 228,163	$ 415,331
Accrued royalty and contingent legal fees	577,190	449,691
Accrued collaborative research and license expense	147,410	30,000
Accrued other	20,072	6,003
Accrued expenses	$ 972,835	$ 901,025

Net Loss Per Share of Common _2

Net Loss Per Share of Common Stock (Details Narrative) - shares	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Stock Options [Member]
Antidilutive shares	8,659,134	8,407,234
Warrants [Member]
Antidilutive shares	560,000	500,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Jan. 31, 2021	Jan. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized income tax benefits, penalties

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended
	Jan. 31, 2021USD ($)	Jan. 31, 2020USD ($)ft²
Rent expenses	$ 16,000	$ 16,000
Almaden Expressway, San Jose [Member]
Area of land | ft²		2,000
Operating lease, expiration date	Sep. 30, 2021
Rent expenses	$ 5,000
Rent percentage	3.00%
Operating lease remaining term		8 months

Leases - Schedule of Operating

Leases - Schedule of Operating Lease (Details) - USD ($)	Jan. 31, 2021	Oct. 31, 2020
Leases [Abstract]
Right-of-use asset	$ 40,212	$ 54,340
Right-of-use liability, current	$ 40,836	$ 55,198

Leases - Schedule of Minimum Le

Leases - Schedule of Minimum Lease Payments (Details)	Jan. 31, 2021USD ($)
Leases [Abstract]
2021 future minimum payments, undiscounted	$ 43,008
Less: Imputed interest	(2,172)
Present value of future minimum lease payments	$ 40,836

Segment Information (Details Na

Segment Information (Details Narrative)	3 Months Ended
	Jan. 31, 2021USD ($)Numbers	Jan. 31, 2020USD ($)
Segment Reporting [Abstract]
Number of Reportable Segments | Numbers	5
Revenues	$ 512,500
Inventor royalties, contingent legal fees, litigation and licensing expenses	$ 385,002

Segment Information - Schedule

Segment Information - Schedule of Segment Information (Details) - USD ($)	3 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Oct. 31, 2020
Net Loss	$ (2,232,377)	$ (2,616,575)
Total operating costs and expenses	2,745,631	2,629,869
Less non-cash share-based compensation	(986,099)	(1,021,334)
Operating costs and expenses excluding non-cash share-based compensation	1,759,532	1,608,535
Total assets	14,604,402	9,452,964	$ 9,452,964
CAR-T Therapeutics [Member]
Net Loss	(960,736)	(630,333)
Operating costs and expenses excluding non-cash share-based compensation	557,680	346,341
Total assets	5,849,920	2,988,124
Cancer Vaccines [Member]
Net Loss	(906,336)	(195,596)
Operating costs and expenses excluding non-cash share-based compensation	537,988	98,270
Total assets	5,822,106	946,923
Anti-Viral Therapeutics [Member]
Net Loss	(480,806)
Operating costs and expenses excluding non-cash share-based compensation	270,256
Total assets	2,775,760	2,464,361
Cancer Diagnostics [Member]
Net Loss	(8,962)	(1,790,646)
Operating costs and expenses excluding non-cash share-based compensation	6,432	1,163,924
Total assets	85,463	2,869,529
Patent Licensing [Member]
Net Loss	124,463
Operating costs and expenses excluding non-cash share-based compensation	387,176
Total assets	$ 71,153	$ 184,027